Form 4: Health Catalyst CFO Sells Shares Under Pre-Arranged Trading Plan

Health Catalyst's Chief Financial Officer, Jason Alger, sold 19,599 shares of common stock at a price of $8.3193 per share, totaling $86,712, under a pre-arranged trading plan.

Summary

• Health Catalyst's Chief Financial Officer, Jason Alger, executed a sale of 19,599 shares of the company's common stock.
• The sale occurred on December 6, 2024, at a price of $8.3193 per share.
• The total value of the shares sold amounted to $86,712.
• This transaction was conducted under a pre-arranged trading plan adopted on March 13, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale by an executive under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for a company insider and is not unusual. It is common for executives to use pre-arranged trading plans to sell shares to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive stock sales are a common occurrence in publicly traded companies, and the use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
• The size of this transaction is relatively small compared to the overall market capitalization of Health Catalyst, and is not likely to have a significant impact on the stock price.

Stakeholder Impact

• The stock sale by the CFO may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect on the company's operations or financial health.

Key Dates

Keywords

Health Catalyst, HCAT, Jason Alger, CFO, stock sale, Rule 10b5-1, trading plan